Security key
69353Y103
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP)
CUSIP: 69353Y103
Q1 2022 13F Holders as of 31 Mar 2022
- Security type / class
- Equity / Common stock, par value $0.00001
- Total 13F shares
- 55,249,345
- Total 13F value
- $1,150,065,944
- Share change
- +7,872,487
- Put/Call ratio
- 77%
- SEC-reported price per share
- $20.82
- Number of holders
- 98
- Value change
- +$162,099,243
- Number of buys
- 48
- Number of sells
- 47
- Shares outstanding
- 53,394,523
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2022
Institutions
98
Top holders
10
PMVP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2022
Previous quarter: Q4 2021
PMV Pharmaceuticals, Inc. SEC filings
PMV Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 69353Y103
Recent filing periods:
Ownership snapshot
Top reported holders of PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2021
13F
3/4/5
Lead comparable stake: 14%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
14%
INTERWEST VENTURE MANAGEMENT CO
6.1%
JPMORGAN CHASE & CO
5.9%
RTW INVESTMENTS, LP
5.6%
Boxer Capital, LLC
5.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
14%
|
$169,333,000
7,330,423 shares
|
— | 31 Dec 2021 |
| INTERWEST VENTURE MANAGEMENT CO |
13F
Company
|
6.1%
|
$74,726,000
3,234,911 shares
|
— | 31 Dec 2021 |
| JPMORGAN CHASE & CO |
13F
Company
|
5.9%
|
$73,164,000
3,167,222 shares
|
— | 31 Dec 2021 |
| RTW INVESTMENTS, LP |
13F
Company
|
5.6%
|
$68,860,000
2,980,960 shares
|
— | 31 Dec 2021 |
| Boxer Capital, LLC |
13F
Company
|
5.3%
|
$65,563,000
2,838,236 shares
|
— | 31 Dec 2021 |
| VANGUARD GROUP INC |
13F
Company
|
5%
|
$61,167,000
2,647,946 shares
|
— | 31 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
98
Shares
55,249,345
Rows available
98
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2022 vs Q4 2021 Across Filers
Q4 2021 holders
102
Q1 2022 holders
98
Holder diff
-4
| Investor | Q4 2021 Shares | Q1 2022 Shares | Share Diff | Share Chg % | Q4 2021 value | Q1 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend